CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹36,742 Cr | ₹32,130 Cr | ₹29,007 Cr | ₹26,652 Cr | ₹24,837 Cr |
What is the latest Total Liabilities ratio of CIPLA ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹36,742 Cr |
| Mar2024 | ₹32,130 Cr |
| Mar2023 | ₹29,007 Cr |
| Mar2022 | ₹26,652 Cr |
| Mar2021 | ₹24,837 Cr |
How is Total Liabilities of CIPLA Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹36,742 Cr | 14.35 | |
| Mar2024 | ₹32,130 Cr | 10.77 | |
| Mar2023 | ₹29,007 Cr | 8.83 | |
| Mar2022 | ₹26,652 Cr | 7.31 | |
| Mar2021 | ₹24,837 Cr | - | |
Compare Total Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹122,054.5 Cr | 1.1% | 0.2% | -1.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹414,929.0 Cr | 0.7% | -4.2% | -8.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,644.0 Cr | 0% | -1% | 4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹131,481.0 Cr | 2.4% | 4.5% | 14.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹104,784.0 Cr | -1% | -2% | -9.7% | Stock Analytics | |
| MANKIND PHARMA | ₹90,922.4 Cr | 1% | -0.2% | -24.9% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 1.1% |
0.2% |
-1.9% |
| SENSEX | 0.9% |
0.7% |
9.6% |
You may also like the below Video Courses